About: Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
Creator	Hung, Chien-Fu Wu, T-C Chuang, Chi-Mu Monie, Archana
source	Medline; PMC
abstract	BACKGROUND: There is an urgent need to develop new innovative therapies for the control of advanced cancer. The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control of advanced cancer. METHODS: In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 (HPV-16) E7 antigen (CRT/E7) with the TLR7 agonist imiquimod for their ability to generate E7-specific immune responses and antitumor effects in tumor-bearing mice. RESULTS: We observed that treatment with CRT/E7 DNA in combination with imiquimod leads to an enhancement in the E7-specific CD8+ T cell immune responses and a decrease in the number of myeloid-derived suppressor cells in the tumor microenvironment of tumor-bearing mice. Furthermore, treatment with CRT/E7 DNA in combination with imiquimod leads to significantly improved antitumor effects and prolonged survival in treated mice. In addition, treatment with imiquimod led to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment. Macrophages and NK1.1+ cells were found to play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod. CONCLUSIONS: Thus, our data suggests that the combination of therapeutic HPV DNA vaccination with topical treatment with the TLR7 agonist imiquimod enhances the antitumor immunity induced by DNA vaccination. The current study has significant implications for future clinical translation.
has issue date	2010-04-28(xsd:dateTime)
bibo:doi	10.1186/1423-0127-17-32
bibo:pmid	20426849
has license	cc-by
sha1sum (hex)	a762208186ddb3827966e6d7bec5a4fb8a0124cf
schema:url	https://doi.org/10.1186/1423-0127-17-32
resource representing a document's title	Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
has PubMed Central identifier	PMC2873498
has PubMed identifier	20426849
schema:publication	J Biomed Sci
resource representing a document's body	covid:a762208186ddb3827966e6d7bec5a4fb8a0124cf#body_text
is schema:about of	named entity 'ACCESS' named entity 'The combination' named entity 'Treatment' named entity 'THERAPEUTIC' named entity 'APPROACH' named entity 'URGENT' named entity 'EMPLOYMENT' named entity 'BACKGROUND' named entity 'ADVANCED CANCER' named entity 'NEED' named entity 'IMMUNITY' named entity 'NEW' named entity 'RESEARCH TREATMENT' named entity 'HPV DNA' named entity 'DNA VACCINATION' named entity 'THERAPIES' named entity 'ANTITUMOR' named entity 'OPEN' named entity 'IMIQUIMOD' named entity 'INDUCED' named entity 'ANTIGEN-SPECIFIC IMMUNOTHERAPY' named entity 'COMBINATION' named entity 'CONTROL' named entity 'IMMUNOMODULATORY' covid:arg/a762208186ddb3827966e6d7bec5a4fb8a0124cf named entity 'National Cancer Institute' named entity 'CD8' named entity 'myeloid-derived suppressor cells' named entity 'antitumor' named entity 'abdominal region' named entity 'DNA vaccines' named entity 'immune responses' named entity 'Line graph' named entity 'tumor' named entity '2, 3' named entity 'vaccination' named entity 'F4/80' named entity 'tumor' named entity 'intracellular' named entity 'subcutaneously' named entity 'CRT' named entity 'HPV-16' named entity 'nucleocapsid protein' named entity 'flow cytometry' named entity 'imiquimod' named entity 'flow cytometric' named entity 'NK1' named entity 'tumor size' named entity 'specific immunotherapy' named entity 'significant difference' named entity 'Gr-1' named entity 'CD25' named entity 'tumors' named entity 'imiquimod' named entity 'tumor growth' named entity 'preclinical models' named entity 'TLR7' named entity 'NK1' named entity 'CRT' named entity 'immune responses' named entity 'tumor microenvironment' named entity 'specific immunotherapy' named entity 'Tumor' named entity 'CRT' named entity 'tumor' named entity 'antitumor' named entity 'CRT' named entity 'regulatory T cells' named entity 'imiquimod' named entity 'TLR7' named entity 'tumor' named entity 'cell surface' named entity 'IL-6' named entity 'standard deviation' named entity 'imiquimod' named entity 'DNA construct' named entity 'NK cells' named entity 'CRT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software